VPS4A inhibitor / Calithera - LARVOL DELTA

Identification of novel VPS4A inhibitors for the treatment of VPS4B-deleted cancers (AACR 2022) - "We have discovered a novel series of VPS4A inhibitors and are advancing this inhibitor series through lead optimization. Potent, selective, and pharmacologically active VPS4A inhibitors are expected to be well tolerated and have strong single-agent activity in tumors bearing VPS4B homozygous deletions."

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • SMAD2 • SMAD4

Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds (GlobeNewswire) - "Calithera Biosciences...shared new data today from the company’s preclinical synthetic lethality program. The findings, which are now available as an e-poster and will be presented live on April 11 at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Abstract #1816), validate the synthetic lethal interaction between the gene paralogs vacuolar protein sorting-associated protein 4A (VPS4A) and 4B (VPS4B)....Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers."

Preclinical • Oncology • Solid Tumor